Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 5, 1998, Pages 769-776

  Herzer, William A ^a   Thomas, Neal J ^a   Carcillo, Joseph A ^a   Tofovic, Stevan P ^a   Jackson, Edwin K ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cardiac function; Catecholamine; Cyclic AMP; Ro 20 1724; Type IV phosphodiesterase

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ADRENALIN; CATECHOLAMINE; CYCLIC AMP; DIMETHYL SULFOXIDE; DOBUTAMINE; DRUG VEHICLE; ISOPRENALINE; NORADRENALIN; PHOSPHODIESTERASE IV INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG EFFECT; ENZYME INHIBITION; HEART FUNCTION; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HEART RATE; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT;

4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; ANIMALS; CATECHOLAMINES; DOBUTAMINE; DRUG INTERACTIONS; EPINEPHRINE; HEMODYNAMIC PROCESSES; ISOPROTERENOL; MALE; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031766265     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199811000-00013     Document Type: Article

References (37)

1. Molnar-Kimber K, Yonno L, Heaslip R, Weichman B. Modulation of TNFα and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 1993;39(Special Conference Issue):C77-9.
2. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 1993;15:409-13.
3. Verghese MW, McConnell RT, Strickland AB, et al. Differential regulation of human monocyte-derived TNFα and IL-1β by type IV cAMP-phosphodiesterase inhibitors. J Pharmacol Exp Ther 1995;272:1313-20.
4. Prabhakar U, Lipshutz D, O'Leary Bartus J, et al. Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV inhibitor. Int J Immunopharmacol 1994;16:805-16.
5. Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J Immunol 1995;155:4909-16.
6. Schade FU, Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol 1993;230: 9-14.
7. Begany DP, Carcillo JA, Herzer WA, Mi Z, Jackson EK. Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. J Pharmacol Exp Ther 1996;278:37-41.
8. Carcillo JA, Herzer WA, Mi Z, Thomas NJ, Jackson EK. Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine. J Pharmacol Exp Ther 1997;279:1197-204.
9. Turner CR, Esser KM, Wheeldon EB. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. Circ Shock 1993;39:237-15.
10. Lagente V, Hichami A, Boichot E, Martins MA. Silva PMR. Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors. Allerg Immunol (Paris) 1995;27:34-9.
11. Khan MM, Townley RG. Cytokine studies in allergy and asthma. Proc West Pharmacol Soc 1994;37:105-6.
12. Karlsson J-A, Souness J, Webber S, Pollock K, Raeburn D. Anti-inflammatory effects of the novel phosphodiesterase IV inhibitor RP 73401. Int Arch Allerg Immunol 1995;107:425-6.
13. Schudt C, Tenor H, Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 1995;8:1179-83.
14. Sommer N, Loschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1995;1:244-8.
15. Dinter H, Onuffer J, Faulds D, Perez HD. Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. J Mol Med 1997;75:95-102.
16. Angel JB, Saget BM, Walsh SP, et al. Specific type IV phosphodiesterase inhibitor is a potent inhibitor of HIV-1 replication. AIDS... 1995;9:1137-44.
17. Hall IP. Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br J Pharmacol 1993;35:1-7.
18. Thompson WJ. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry, and function. Pharmacol Ther 1991;51:13-33.
19. Murray KJ, England PJ. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents. Biochem Soc Trans 1992;20:460-4.
20. Nicholson CD, Challis RA, Shadid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 1991;12:19-27.
21. Evans DB. Overview of cardiovascular physiologic and pharmacologic aspects of selective phosphodiesterase peak III inhibitors. Am J Cardiol 1989;63:9A-11A.
22. Honerjager P. Pharmacology of positive inotropic phosphodiesterase III inhibitors. Eur Heart J 1989:10(suppl C):25-31.
23. Rettig GF, Schieffer HJ. Acute effects of intravenous milrinone in heart failure. Eur Heart J 1989:10(suppl C):39-L3.
24. Colucci WS. Myocardial and vascular actions of milrinone. Eur Heart J 1989:10(suppl C):32-8.
25. Chatterjee K. Newer oral inotropic agents: phosphodiesterase inhibitors. Crit Care Med 1990;18:534-8.
26. Laycock SK, Kane KA, McMurray J, Parratt JR. Captopril and norepinephrine-induced hypertrophy and haemodynamics in rats. J Cardiovasc Pharmacol 1996;27:667-72.
27. Gartner SL, Vahouny GV, Effects of epinephrine and cyclic 3′, 5′-AMP on perfused rat hearts. Am J Physiol 1972;222:1121-4.
28. Robinson GA, Butcher RW, Oye I, Morgan HE, Sutherland EW. The effects of epinephrine on adenosine 3′, 5′-phosphate levels in the isolated perfused rat heart. Mol Pharmacol 1965;1:168-77.
29. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996:199-248.
30. Cui Y, Shen Y-T, Kalthof B, et al. Identification and functional role of β-adrenergic receptor subtypes in primate and rodent: in vivo versus isolated myocytes. J Mol Cell Cardiol 1996;28:1307-17.
31. Ruffolo RR Jr, Messick K. Effects of dopamine, (±)-dobutamine and the (+)- and (-)-enantiomers of dobutamine on cardiac function in pithed rats. J Pharmacol Exp Ther 1985:235:558-65.
32. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975;36:185-96.
33. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 1987;61:539-47.
34. Shahid M, Nicholson CD. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn Schmiedebergs Arch Pharmacol 1990;342:698-705.
35. Sugioka M, Ito M, Masuoka H, et al. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes. Naunyn Schmiedebergs Arch Pharmacol 1994;350:284-93.
36. Katano Y, Endoh M. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine. J Cardiovasc Pharmacol 1992;20: 715-22.
37. Kelso EJ, McDermott BJ, Silke B. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes. Br J Pharmacol 1993;110:1387-94.